Loading
A phase 2 trial of fulzerasib in lung cancer, run by Jianxing He, now recruiting.
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC is a phase 2, interventional study registered as NCT07492342 by Jianxing He, with a registry enrolment figure of 30 participants, started 2026-01-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: fulzerasib. Conditions listed: Resectable NSCLC; KRAS G12C Mutation; Stage IB-IIIA NSCLC; Neoadjuvant Therapy. Primary outcome: Pathological Complete Response, pCR. Lung eligibility wording from the registry: "Histologically or cytologically confirmed primary non-small cell lung cancer (NSCLC)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Fulzerasib, Innovent Biologics, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag lung-deep-dive.
Shares Innovent Biologics, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.